Upper Safe Limit
No UL established; 100-300mg/day (>0.2% parthenolide) used in trials
PubMed Studies
12
PubChem CID
About
Feverfew has good evidence for migraine prevention (not treatment). Long-term use (>3 months) is required for benefit. EMA monograph confirms traditional use for migraine prevention.
How it works (mechanism of action)
Parthenolide inhibits platelet aggregation, inhibits prostaglandin synthesis, inhibits NF-kB, and blocks serotonin release from platelets (relevant to migraine pathophysiology).
📊 Effectiveness
Migraine prevention
Evidence Grade A · 12 studies · n=580 · Meta-analysis available
Evidence grades: A=Strong RCT evidence · B=Good clinical trials · C=Limited trials · D=Preliminary/traditional
👥 Safety by Population
🚫 Contraindications & Warnings
Post-feverfew syndrome on discontinuation: rebound headaches, joint pain, anxiety. Avoid in pregnancy (uterotonic). May interact with blood thinners. Take with food to reduce GI side effects.
💊 Drug Interactions (2)
🟡 Warfarin
ModerateAnticoagulant
Management: Monitor INR. Stop 2 weeks before surgery.
🟡 NSAIDs
ModerateAnti-inflammatory
Management: Caution with concurrent use.
🏷️ Other Names
Tanacetum parthenium